2020

7TH ANNUAL GLOBAL SUMMIT ON HEMATOLOGIC MALIGNANCIES

MARCH 11-15, 2020
Fairmont Chateau Whistler
Whistler, BC, Canada

JOIN OUR CHAIRS

STEVE COUTRÉ, MD
Stanford University School of Medicine

JOSEPH MIKAEL, MD, MED, FRCPC, FACP
Translational Genomics Research Institute
City of Hope

RICHARD STONE, MD
Dana-Farber Cancer Institute
Harvard Medical School

ANDREW ZELENETZ, MD, PHD
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College

FOR MORE INFORMATION OR TO REGISTER, VISIT: HTTP://BIT.LY/WHISTLER2020.
CHAIRS

STEVE COUTRÉ, MD
Professor of Medicine, Hematology
Stanford University School of Medicine
Stanford, CA

JOSEPH MIKHAEL, MD, MED, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
City of Hope
Phoenix, AZ

RICHARD STONE, MD
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

ANDREW ZELENETZ, MD, PHD
Medical Director, Quality Informatics Attending Physician
Memorial Sloan Kettering Cancer Center
Professor
Weill Cornell Medical College
New York, NY

JOHN ALLAN, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, NY

PAMELA BLAIR ALLEN, MD, MSC
Assistant Professor, Department of Hematology and Medical Oncology
Emory Winship Cancer Institute
Atlanta, GA

MICHAEL ANDREEFF, MD, PHD
Professor of Medicine
Paul and Mary Haas Chair in Genetics Chief, Molecular Hematology and Therapy
Departments of Leukemia and Stem Cell Transplantation and Cellular Therapy
University of Texas MD Anderson Cancer Center
Houston, TX

DAVID AVIGAN, MD
Chief, Division of Hematology and Hematologic Malignancies
Beth Israel Deaconess Medical Center
Co-Director, Immunotherapy Institute
Cancer Center and Rosenberg Clinical Cancer Center
Professor of Medicine
Harvard Medical School
Boston, MA

VERONIKA BACHANOVA, MD
Associate Professor of Medicine
University of Minnesota
Minneapolis, MN

WILLIAM BENSINGER, MD
Director, Myeloma Program
Myeloma and Transplant Program
Swedish Cancer Institute
Seattle, WA

JAMES BERENSON, MD
President and CEO
Medical and Scientific Director
Institute for Myeloma and Bone Cancer Research
Los Angeles, CA

PRITHVIRAJ BOSE, MD
Associate Professor
University of Texas MD Anderson Cancer Center
Houston, TX

BEN BUELOW, MD, PHD
Chief Medical Officer
Tenebrio
Newark, CA

ELISE CHONG, MD
Assistant Professor of Medicine
Associate Director, Lymphoma Clinical Trials Research Unit
Lymphoma Program, Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

ANDREW COWAN, MD
Assistant Member, Clinical Research Division
Fred Hutchinson Cancer Center
Assistant Professor of Medicine, Division of Medical Oncology
University of Washington School of Medicine
Seattle, WA

ALEXEY V. DANILOV, MD, PHD
Professor of Medicine
Associate Director, Toni Stephenson Lymphoma Center
City of Hope National Medical Center
Los Angeles, CA

PINKAL DESAI, MD, MPH
Assistant Professor of Medicine
Weill Cornell Medical College
Assistant Attending Physician
New York-Presbyterian Hospital
New York, NY

SVEN DE VOS, MD, PHD
Associate Professor
David Geffen School of Medicine at UCLA
Los Angeles, CA

VARSHA GANDHI, PHD
Professor and Chair, ad interim
Department of Experimental Therapeutics
University of Texas MD Anderson Cancer Center
Houston, TX

BRIAN HILL, MD, PHD
Director, Lymphoid Malignancies Program
Associate Professor
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

NITIN JAIN, MD
Associate Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, TX

THOMAS KIPPS, MD, PHD
Distinguished Professor of Medicine
UC San Diego Health, Moores Cancer Center
La Jolla, CA

SHAJI KUMAR, MD
Professor of Medicine
Mayo Clinic
Rochester, MN

HANS LEE, MD
Assistant Professor
University of Texas MD Anderson Cancer Center
Houston, TX
THOMAS MARTIN, MD
Professor of Clinical Medicine
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

NEHA MEHTA-SHAH, MD
Assistant Professor of Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO

SOHEIL MESHINCHI, MD, PHD
Professor of Medicine
Fred Hutchinson Cancer Center
University of Washington School of Medicine
Seattle, WA

DAVID MIKLOS, MD, PHD
Clinical Director of Cancer Cell Therapy
Associate Professor of Medicine
Stanford University
Stanford, CA

CLIFTON MO, MD
Medical Oncologist
Dana-Farber Cancer Institute
Boston, MA

ALISON MOSKOWITZ, MD
Clinical Director and Assistant Attending, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, NY

OMAR NADEEM, MD
Medical Oncologist
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Instructor in Medicine
Harvard Medical School
Boston, MA

LORETTA NASTOUPI, MD
Associate Professor
Department of Lymphoma/Myeloma
University of Texas MD Anderson Cancer Center
Houston, TX

JOHN PAGEL, MD, PHD
Chief of Hematologic Malignancies
Director of Hematopoietic Stem Cell Transplantation Program
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute
Seattle, WA

KRISH PATEL, MD
Director, Lymphoma Program
Center for Blood Disorders and Stem Cell Transplantation
Swedish Medical Center
Seattle, WA

DAVID SIEGEL, MD, PHD
Director
Multiple Myeloma Institute
Hackensack University Medical Center
Hackensack, NJ

EDWARD STADTMUER, MD
Section Chief, Hematologic Malignancies
Roseman, Tarte, Harrow, and Shaffer Families’ President’s Distinguished Professor
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

A. KEITH STEWART, MB, CHB
Carlson and Nelson Endowed Director, Center for Individualized Medicine
Vasek and Anna Maria Polak Professor of Cancer Research
Professor of Medicine
Mayo Clinic
Scottsdale, AZ

STEVEN TREON, MD, PHD, FRCP, FACP
Director, Bing Center for Waldenstrom’s Macroglobulinemia
Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

RAVI VIJ, MD, MBA
Professor of Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO

EUNICE S. WANG, MD
Chief, Leukemia Service
Professor of Oncology, Department of Medicine
Roswell Park Comprehensive Cancer Institute
Buffalo, NY

ADRIAN WIESTNER, MD, PHD
Chief, Lymphoid Malignancies Section
NIH National Heart, Lung, and Blood Institute
Bethesda, MD

JEFFREY A. ZONDER, MD
Professor of Oncology
Multiple Myeloma and Amyloidosis Multidisciplinary Team Leader
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, MI
Wednesday, March 11, 2020

Setting the Stage

5:00 pm   Welcome and Introductions
5:15 pm   How Can MRD Be Used in Hematologic Malignancies in 2020?  William Bensinger*
5:30 pm   Clinical Impact of Clonal Evolution in CLL  TBD
6:00 pm   Current State of NHL  Andrew Zelenetz
6:15 pm   Implications of Molecular Subtyping of DLBCL for Clinical Trial Design  Brian Hill
6:30 pm   PANEL DISCUSSION
7:00 pm   BREAK
7:15 pm   How Many Drugs Do We Need in Frontline MM?  Nina Shah
7:30 pm   Genomics of Myeloma: Single Cell Sequencing and Personalized Medicine  Ravi Vij
7:45 pm   Treatment-free Remission in CML: Is This a Model for Other Chronic Hematologic Malignancies?  Charles Schiffer
8:00 pm   Results of the BEAT-AML Trial: Timing for Cytogenetics and Molecular Testing  Eunice Wang
8:15 pm   PANEL DISCUSSION
8:45 pm   ADJOURN TO WELCOME RECEPTION

Thursday, March 12, 2020

Chronic Lymphocytic Leukemia

7:00 am   Evolving Role of Single-agent BTKi in Frontline CLL  John Pagel*
7:15 am   Role of Next-generation BTK Inhibitors in CLL  John Allan
7:30 am   How to Approach a Patient at First Relapse?  Steve Coutré
7:45 am   Targeted Protein Degradation: A Novel Strategy to Overcome BTKi Resistance  Adrian Wiestner
8:00 am   Evolving Field of BTK in WM  Steven Treon
8:15 am   PANEL DISCUSSION
8:45 am   BREAK
8:45 am   Expectations for Novel-novel Combination Therapy  Varsha Gandhi
9:00 am   Lessons Learned on Using Venetoclax in CLL  Thomas Kipps
9:15 am   How to Approach Venetoclax Resistance  Alexey Danilov
9:30 am   PANEL DISCUSSION
10:00 am  BREAK
10:15 am  Emerging Agent Showcase  TBD
10:30 am  Emerging Agent Showcase  TBD
10:45 am  PANEL DISCUSSION
11:00 am  Rationale for Combining Anti-CD20s with Targeted Therapies  John Allan*
11:15 am  What Is the Status of CAR-T in CLL  Thomas Kipps
11:30 am  Bi-specifics and Immunotherapy in CLL  John Pagel*
11:45 am  PANEL DISCUSSION
12:00 pm  ADVISORY BOARDS

Friday, March 13, 2020

Multiple Myeloma

7:00 am   When Do I Treat Smoldering Myeloma?  Omar Nadeem
7:15 am   Discussion: What Will Be the New Frontline Treatment in MM in 2020?  Joseph Mikhael
8:00 am   What Is the Optimal Maintenance Therapy in MM in 2020?  Donna Reece
8:15 am   PANEL DISCUSSION
8:30 am   What Role Will Isatuximab Play in R/R MM?  Thomas Martin*
8:45 am   Will Venetoclax Be a MM Drug?  Keith Stewart
9:00 am   Where Is Selinexor Going to Fit in the MM Landscape Post-approval?  James Berenson*
9:15 am   PANEL DISCUSSION
9:45 am   BREAK
10:00 am  Emerging Agent Showcase: Melflufen  TBD
10:15 am  Emerging Agent Showcase: Teneobio  Ben Buelow
10:30 am  PANEL DISCUSSION

*Pending speaker approval of presentation title.
AGENDA CONTINUED

Agenda subject to change.

10:45 am Optimal Sequencing for Early Relapse
10:50 am Shaji Kumar*

11:00 am Approaching Treatment Failure in 2020: Unique Challenges
11:05 am Clifton Mo

11:15 am Understanding Daratumumab’s Impact on the Immune System
11:20 am Thomas Martin*

11:30 am Update on Treatment of AL Amyloidosis
11:35 am Jeffrey Zonder

11:45 am PANEL DISCUSSION

12:15 pm ADVISORY BOARDS

Acute Myeloid Leukemia
5:00 pm Understanding the Clinical Significance of Mutational Overlap in AML
5:05 pm Soheil Meshinchi

5:15 pm Apoptosis Induction Beyond BCL2: Potential Role for Targeting p53
5:20 pm Michael Andreeff

5:30 pm Practical Aspects of Managing JAK Inhibitors
5:35 pm Prithviraj Bose

5:45 pm Combination JAKi and Non-JAKi
5:50 pm Naveen Pemmaraju

6:00 pm PANEL DISCUSSION

6:30 pm BREAK

6:45 pm Future Role of MRD in AML
6:50 pm TBD

7:00 pm What Is Next for FLT3 in AML?
7:05 pm Pinkal Desai*

7:15 pm Role of Transplant in AML
7:20 pm TBD

7:30 pm How to Choose Appropriate Induction Therapy for Poor-risk AML
7:35 pm Richard Stone*

7:45 pm Maintenance Therapy in AML
7:50 pm Farhad Ravandi

8:00 pm Targeting the Hedgehog Pathway in AML: Glasdegib
8:05 pm TBD

8:15 pm Novel Immunotherapeutic Targets in AML
8:20 pm Soheil Meshinchi

8:30 pm What Is Next for CAR-T in ALL?
8:35 pm TBD

8:45 pm PANEL DISCUSSION

9:15 pm ADJOURN TO RECEPTION

Saturday, March 14, 2020
6:00 am BREAKFAST

Emerging Trends in NHL and AML
7:00 am Why Have Previous NHL Therapies Failed?
7:05 am Sarah Rutherford

7:15 am Integrating New Therapies into DLBCL Treatment: Can We Get Past R-CHOP?
7:20 am Sven de Vos

7:30 am Cutaneous T-Cell Lymphoma
7:35 am Pamela Allen

7:45 am Incorporating New Targets into PTCL Therapy
7:50 am Alison Moskowitz

8:00 am Treatment Considerations for R/R PTCL in 2020
8:05 am Neha Mehta-Shah*

8:15 am Emerging NK Cell Therapies for Lymphoma
8:20 am TBD

8:30 am Potential Role for EZH2i in NHL
8:35 am Krish Patel

8:45 am PANEL DISCUSSION

9:30 am Novel Emerging Therapies for High-Risk AML and MDS
9:35 am TBD

9:45 am MDM2i-based Therapies: Potential Applications in 2020 and Beyond
9:50 am Richard Stone

10:00 am Venetoclax-based Resistance and Novel Combinations for AML
10:05 am TBD

10:15 am Immune Checkpoint-based Treatment in AML
10:20 am TBD

10:30 am Novel Mechanistic Antibodies for AML
10:35 am Eunice Wang

10:45 am PANEL DISCUSSION

11:45 am ADJOURN

12:00 pm ADVISORY BOARDS

Panel Discussion: Can We Overcome the Inefficiencies in Our Current Clinical Trial System?
5:00 pm PANEL DISCUSSION

Emerging Trends in CLL and MM
5:45 pm Impact of BTKi on Immune Function: Experience with Bispecifics
5:50 pm Adrian Wiestner

6:00 pm Emerging Agent Showcase
6:05 pm TBD

6:15 pm Emerging Agent Showcase
6:20 pm TBD

6:30 pm PANEL DISCUSSION

7:00 pm BREAK

7:15 pm BCMA Antibody Drug Conjugates for MM
7:20 pm Hans Lee

7:30 pm BCMA CAR-T for MM: Current Data
7:35 pm David Siegel

7:45 pm BCMA CAR-T for MM: Future Directions
7:50 pm Noopur Raje

8:00 pm BCMA Bi-/Tri-specific Antibodies for MM
8:05 pm William Bensinger

8:15 pm What is the Best Approach to Target BCMA?
8:20 pm Edward Stadtmauer*

8:30 pm Non-BCMA Targets for CAR-T, BiTEs, and Other Immunotherapies
8:35 pm Andrew Cowan

8:45 pm PANEL DISCUSSION

9:15 pm ADJOURN

Sunday, March 15, 2020
6:00 am BREAKFAST

Oral Abstracts
7:00 am - 8:10 am Oral Abstracts
8:10 am PANEL DISCUSSION
8:30 am ADJOURN

*Pending speaker approval of presentation title.